Helen Sabzevari - 24 Jun 2021 Form 4 Insider Report for Kinnate Biopharma Inc.

Role
Director
Signature
/s/ Mark Meltz, attorney-in-fact
Issuer symbol
N/A
Transactions as of
24 Jun 2021
Net transactions value
$0
Form type
4
Filing time
28 Jun 2021, 13:04:09 UTC
Previous filing
14 May 2021
Next filing
20 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Award $0 +40,501 $0.000000 40,501 24 Jun 2021 Common Stock 40,501 $24.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/36th of the shares underlying the Option vest and become exercisable on each monthly anniversary of the Date of Grant.